Trials / Completed
CompletedNCT00434785
A Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 in Healthy Japanese Males
An Ascending, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Healthy Male Japanese Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
To assess the safety and tolerability of ascending, multiple oral doses of AGG-523 in healthy Japanese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGG-523 |
Timeline
- Start date
- 2007-02-01
- Completion
- 2007-09-01
- First posted
- 2007-02-13
- Last updated
- 2007-12-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00434785. Inclusion in this directory is not an endorsement.